Consensus report: definition and interpretation of remission in type 2 diabetes

[1]  F. Rubino,et al.  Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial , 2021, The Lancet.

[2]  W. Herman,et al.  Metformin Should Be Used to Treat Prediabetes in Selected Individuals , 2020, Diabetes Care.

[3]  M. Davidson Metformin Should Not Be Used to Treat Prediabetes , 2020, Diabetes Care.

[4]  K. Khunti,et al.  Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis , 2020, BMJ.

[5]  W. Ming,et al.  Incidence Rate of Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 170,139 Women , 2020, Journal of diabetes research.

[6]  K. Li,et al.  [Plasmodium falciparum infection complicated by bronchopneumonia in a peacekeeper: a case report]. , 2020, Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control.

[7]  R. Beck,et al.  Continuous Glucose Monitoring Profiles in Healthy Non-Diabetic Participants: A Multicenter Prospective Study. , 2019, The Journal of clinical endocrinology and metabolism.

[8]  Roy Taylor,et al.  Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) , 2019, British Journal of Diabetes.

[9]  Angela M Rodrigues,et al.  Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[10]  Benjamin S. Aribisala,et al.  Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.

[11]  R. Beck,et al.  Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring , 2018, Diabetes Care.

[12]  Thomas P. Smith,et al.  EurA1c: The European HbA1c Trial to Investigate the Performance of HbA1c Assays in 2166 Laboratories across 17 Countries and 24 Manufacturers by Use of the IFCC Model for Quality Targets. , 2018, Clinical chemistry.

[13]  Eyal Dassau,et al.  International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.

[14]  Roy W Beck,et al.  The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading , 2017, Diabetes Care.

[15]  H. Gerstein,et al.  Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial , 2017, The Journal of clinical endocrinology and metabolism.

[16]  L. Genser,et al.  Bariatric surgery versus intensive medical therapy for diabetes -5- year outcomes , 2017 .

[17]  Deepak L. Bhatt,et al.  Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes , 2017, The New England journal of medicine.

[18]  W. Herman,et al.  Reconciliation of Type 2 Diabetes Remission Rates in Studies of Roux-en-Y Gastric Bypass , 2016, Diabetes Care.

[19]  Roy Taylor,et al.  Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction , 2016, Diabetes Care.

[20]  B. Zinman,et al.  Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes , 2016, BMJ Open Diabetes Research and Care.

[21]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[22]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations , 2016, Diabetes Care.

[23]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations , 2016, Obesity Surgery.

[24]  A. MacCormick,et al.  Progression of diabetic retinopathy after bariatric surgery , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[25]  Deepak L. Bhatt,et al.  Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes , 2015, Diabetes Care.

[26]  B. Zinman,et al.  Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. , 2013, The lancet. Diabetes & endocrinology.

[27]  Haiying Chen,et al.  Association of an intensive lifestyle intervention with remission of type 2 diabetes. , 2012, JAMA.

[28]  A. Ceriello The emerging challenge in diabetes: the "metabolic memory". , 2012, Vascular pharmacology.

[29]  D. Yue,et al.  Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? , 2012, ISRN endocrinology.

[30]  Benjamin S. Aribisala,et al.  Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.

[31]  C. Fox,et al.  Low Hemoglobin A1c and Risk of All-Cause Mortality Among US Adults Without Diabetes , 2010, Circulation. Cardiovascular quality and outcomes.

[32]  R. Klein,et al.  Glycated Hemoglobin and the Risk of Kidney Disease and Retinopathy in Adults With and Without Diabetes , 2010, Diabetes.

[33]  R. Heine,et al.  Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.

[34]  C. Fox,et al.  Low Hemoglobin A 1 c and Risk of All-Cause Mortality Among US Adults Without Diabetes April , 2010 .

[35]  Sonia Caprio,et al.  How Do We Define Cure of Diabetes? , 2009, Diabetes Care.

[36]  G. Treviño Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation , 2007, Diabetes Care.

[37]  E. Barnes Between remission and cure: patients, practitioners and the transformation of leukaemia in the late twentieth century , 2007, Chronic illness.

[38]  R. Kahn,et al.  Consensus statement on the worldwide standardisation of the HbA 1c measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation , 2007 .

[39]  E. Ferrannini,et al.  β-Cell Function in Severely Obese Type 2 Diabetic Patients , 2007, Diabetes Care.

[40]  M. Panteghini,et al.  The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) , 2006, Clinical chemistry and laboratory medicine.

[41]  R. Taylor,et al.  Long-term progression of retinopathy after initiation of insulin therapy in Type 2 diabetes: an observational study , 2004, Diabetologia.

[42]  S. Inzucchi,et al.  Metformin: new understandings, new uses. , 2003, Drugs.

[43]  R. Paroni,et al.  Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood , 2002, Clinical chemistry and laboratory medicine.

[44]  G. Striker Glucose toxicity. , 2001, Kidney international.

[45]  Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. , 1998, Archives of ophthalmology.

[46]  H. Yki-Järvinen Glucose toxicity. , 1992, Endocrine reviews.

[47]  J. D. Ward,et al.  European association for the study of diabetes , 1987 .